Monthly archive
5 carefully sourced stories published during this month.
Latest GLP-1 news31 July 2026
EMA, MHRA and FDA reviews have not found evidence that GLP-1 medicines increase suicidal thoughts or behaviour. We explain the findings, their limits and why individual experiences still matter.
Read the sourced summary30 July 2026
Oura's GLP-1 Insights combines logged doses, side effects and weight with wearable trends. Here is what the product does, how Lilly is involved and what has not yet been demonstrated.
Read the sourced summary29 July 2026
A careful look at the limited evidence on GLP-1 medicines, sexual desire and relationships, including a randomised dulaglutide trial and an FDA adverse-event database analysis.
Read the sourced summary29 July 2026
A Phase 2 apitegromab study and several registered trials show why obesity-drug research is looking beyond kilograms lost to lean mass, strength and physical function.
Read the sourced summary29 July 2026
A sourced roundup of new Retatrutide Phase 3 results, the US approval of oral orforglipron, Australian NAION warnings and an observational alcohol-hospitalisation study.
Read the sourced summaryEvery published evidence summary remains available in the archive.
